Understand the musculoskeletal partnering landscape using intelligence from 527 real-world collaboration and licensing deals.
Musculoskeletal Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 527 partnering deals involving musculoskeletal assets, technologies and development programs.
Musculoskeletal partnering spans a diverse range of degenerative, inflammatory, injury-related and orthopedic conditions, with transaction structures reflecting different therapeutic approaches, technologies and stages of development.
The report brings this activity together in one resource, enabling users to understand who is partnering, which musculoskeletal opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in musculoskeletal partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable musculoskeletal transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking musculoskeletal opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable musculoskeletal assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building musculoskeletal portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying musculoskeletal deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Musculoskeletal Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 527 partnering deals involving musculoskeletal assets, technologies and development programs.
Musculoskeletal partnering spans a diverse range of degenerative, inflammatory, injury-related and orthopedic conditions, with transaction structures reflecting different therapeutic approaches, technologies and stages of development.
The report brings this activity together in one resource, enabling users to understand who is partnering, which musculoskeletal opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in musculoskeletal partnering.
Understand the musculoskeletal partnering landscape
The report analyzes musculoskeletal dealmaking from 2016 to 2026, including:
- Trends in musculoskeletal partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active musculoskeletal dealmakers
- Leading deals by disclosed value
- How musculoskeletal partnering activity is evolving
Benchmark musculoskeletal deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading musculoskeletal dealmakers and prospective partners
The report identifies the most active companies in musculoskeletal partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking musculoskeletal opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant therapeutic areas
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies or treatment approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across musculoskeletal indications
Musculoskeletal disease encompasses multiple therapeutic areas and treatment approaches with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how musculoskeletal agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected musculoskeletal transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive musculoskeletal deal directory
The report includes a comprehensive directory of 527 musculoskeletal collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable musculoskeletal transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking musculoskeletal opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable musculoskeletal assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building musculoskeletal portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide musculoskeletal intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying musculoskeletal deal intelligence to the customer's own asset, technology, indication or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in musculoskeletal dealmaking
Chapter 3 - Financial deal terms for musculoskeletal partnering
Chapter 4 - Leading musculoskeletal deals and dealmakers
Chapter 5 - Musculoskeletal contract document directory
Chapter 6 - Musculoskeletal dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3D-Side
- 3DR Labs
- 3SBio
- 4P-Pharma
- 4P Therapeutics
- 10X Genomics
- Abbvie
- AbCellera Biologics
- AbTherx
- AC Bioscience
- Accenture
- Aclarion
- Adaptive Biotechnologies
- Advanced Development of Additive Manufacturing
- AdventHealth
- Affinia Therapeutics
- AGC Asahi Glass
- AGC Biologics
- Ageless Biotech
- AgNovos Healthcare
- Akashi Therapeutics
- AKL Research and Development
- Alcyone Therapeutics
- Alexion Pharmaceuticals
- Alfasigma
- Aligos Therapeutics
- Alkem Laboratories
- Allay Therapeutics
- Allegro
- Almirall
- Alpine Immune Sciences
- Altasciences
- Alvogen
- Alvotech
- Ambry Genetics
- Amend Surgical
- American Association of Neuromuscular & Electrodiagnostic Medicine
- American Regent
- Amgen
- Amneal Pharmaceuticals
- Ampersand Biomedicines
- AMRA
- AMRA Medical
- Anagenesis Biotechnologies
- AnaMar
- Andelyn Biosciences
- Angers University
- Anika Therapeutics
- AnnJi Pharmaceutical
- Antibe Therapeutics
- Apple
- Apsen Farmacutica
- Aptahem
- Aptorum Group
- Aratana Therapeutics
- Aravive Biologics
- Archer Daniels Midland Company
- Argenta
- argenx
- ARK Crystal
- Armatus Bio
- Arrowhead Pharmaceuticals
- Arthrosi Therapeutics
- Artialis
- Asahi Kasei
- AskAt
- Asklepios Biopharmaceutical
- Astellas Pharma
- AstraZeneca
- ATEC Spine
- Attwill Medical Solutions
- Audentes Therapeutics
- Augurex Life Sciences
- Aurinia Pharmaceuticals
- Autotelic BIO
- Avalere Health
- Avenue Therapeutics
- Aveta Biomics
- AveXis
- Avidity Biosciences
- Avion Pharmaceuticals
- Axelys
- Axovant Gene Therapies
- Back-A-Line
- Baebies
- Bayer
- Baylor College of Medicine
- BC Platforms
- Beijing Tide Pharmaceutical
- Benitec Biopharma
- Berg
- BGI
- BinnoPharm
- Bio-Thera Solutions
- BioCanRx
- Biogen
- BioGen Medical
- Biohaven Pharmaceuticals
- BioMarin Pharmaceutical
- BioMed X Innovation Center
- Biomimetic Innovations
- BiondVax
- BioNexus Gene Lab
- Bioqube Ventures
- BioRestorative Therapies
- BioSenic
- Bioservo Technologies
- Biosolution
- Biosplice
- Bioventus
- BioVinc
- BirchBioMed
- Bison & Rose
- Blueprint Medicines
- Boehringer Ingelheim
- Bone Biologics
- Bone Therapeutics
- Brain Canada
- Brickell Biotech
- BridgeBio Pharma
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Broad Institute
- Caerus Strength
- California Institute for Regenerative Medicine
- Calimmune
- Camargo Pharmaceutical Services
- Can-Fite BioPharma
- CANbridge Pharmaceuticals
- Capricor Therapeutics
- Capsigen
- CareFirst BlueCross BlueShield
- Carisma Therapeutics
- Carlsmed
- Carna BioSciences
- Cartesian Therapeutics
- Cassie + Friends
- Catabasis Pharmaceuticals
- Catalent
- Catalyst Pharmaceuticals
- cbdMD
- Cedars-Sinai Medical Center
- Celltech
- Cellthera Pharma
- Celltrion
- Cel Sci
- Centogene
- Century Therapeutics
- Cerhum
- CgBio
- Changshan Pharm
- Charles River Laboratories
- CheckPoint Immunology
- Children's Hospital Boston
- Children's Hospital of Philadelphia
- Children's Research Institute
- Chronolife
- Chugai Pharmaceutical
- CHU Sainte-Justine
- Cipla
- City of Hope
- CJ CheilJedang
- Clementia Pharmaceuticals
- CMS Medical
- Coapt
- Cocoon Biotech
- Codiak BioSciences
- Collaborative Trajectory Analysis Project
- Colorado State University
- Columbia University
- Columbia University Medical Center
- ConforMIS
- Coracoid Solutions
- CRISPR Therapeutics
- CrystalGenomics
- CSIR-Central Drug Research Institute
- Cumberland Pharmaceuticals
- Curasan
- Cure Duchenne
- CURE Pharmaceutical
- CurveBeam AI
- CymaBay Therapeutics
- CytoMed Therapeutics
- Cytoo
- Cyxone
- Daewoong Pharmaceutical
- Dalhousie University
- Defense Advanced Research Projects Agency
- Delivra
- Delpor
- Denali Therapeutics
- Department of Defense
- Department of Veterans Affairs
- DePuy
- Distributed Bio
- Dr. Reddy's Laboratories
- Duchenne UK
- Duke University
- DuraStat
- Dynacure
- Dyne Therapeutics
- Dyno Therapeutics
- Echolight Medical
- ECM Therapeutics
- Ecole Polytechnique de Montreal
- Edgewise Therapeutics
- EGeen
- Eisai
- Elanco
- ElevateBio
- Eli Lilly
- Elixirgen Therapeutics
- EmergeOrtho
- Emmyon
- Emory University
- Emovi
- Enable Injections
- ENCell
- Endo International
- Endo Ventures
- Energy Medicine Research Institute
- Engitix
- Enleofen Bio
- Entrada Therapeutics
- Enveric Biosciences
- Enzene Biosciences
- Epicrispr Biotechnologies
- Equillium
- Ethos Research & Development
- Ethypharm
- Eureka Eurostars
- Eurofins LifeCodexx
- EVA Pharma
- Evonik Industries
- EVOQ Therapeutics
- Evotec
- Exagen Diagnostics
- ExCEEd Orphan
- Exicure
- Exonics Therapeutics
- Exothera
- Facio Therapies
- Factor Bioscience
- Feinstein Institute for Medical Research
- Fibrocell Science
- Fin-ceramica faenza spa
- Flexion Therapeutics
- Fluidigm
- Forbius
- Forge Biologics
- Fosun Wanbang
- Frequency Therapeutics
- Fresenius Kabi Pharmaceuticals
- Friends of FSH Research
- FSHD Global Research Foundation
- FUJIFILM Cellular Dynamics
- Fujifilm Kyowa Kirin Biologics
- Fuji Yakuhin
- Fulcrum Therapeutics
- Galapagos
- Galderma
- Galecto
- Galmed Pharmaceuticals
- Gebro Pharma
- GEn1E Lifesciences
- GenEdit
- GeneQuine Biotherapeutics
- General Electric (GE)
- Genethon
- Geneva Foundation
- Genevant Sciences
- Gennao Bio
- Genome BC
- Genome Canada
- Genome Insight
- Genosera
- George Washington University
- Gero
- Gilead Sciences
- GlycoNex
- GPCR Therapeutics
- Graminex
- Graviton Bioscience
- Gravocore
- Great Ormond Street Hospital (GOSH)
- Grunenthal
- GSK
- Guangzhou Ruianbo Pharmaceutical Technology
- Guangzhou Ruiao Biopharmaceutical Technology
- Haisco Pharmaceutical
- HanAll Pharmaceuticals
- Hansa Biopharma
- Hanuman Pelican
- HappyBond
- Harbour Biomed
- Harvard University
- HAYA Therapeutics
- HealthSnap
- HealthTrio
- HemoShear
- Henlius Biotech
- High Line Bio
- Hikma Pharmaceuticals
- HistoIndex
- Horizon Europe
- Horizon Pharma plc
- Horizon Therapeutics
- Hospital for Special Surgery
- Howmedica Osteonics
- Human Life CORD Japan
- Icahn School of Medicine at Mount Sinai
- IDIPharma
- Idorsia
- IGEA Clinical Biophysics
- Iktos
- IM-Tech
- Image Analysis
- ImageBiopsy Lab
- Imcyse
- IMIDomics
- Immunis
- Immuthera
- Impressio
- In2Bones USA
- Incyte
- Indiana University
- Innosuisse
- Innovate UK
- Innovent Biologics
- Innovus Pharmaceuticals
- Inovalon
- Inserm
- Intas Pharmaceuticals
- Integrated Biosciences
- Intel
- Intellia Therapeutics
- International Spine Study Group Foundation
- Intrexon
- Inventiva
- Invibio Biomaterial Solutions
- Invitae
- Ionis Pharmaceuticals
- Ipsen
- IQVIA
- Ironwood Pharmaceuticals
- Italfarmaco
- Izana Bioscience
- Jain Foundation
- Janssen Pharmaceuticals
- Janssen Research & Development
- JCR Pharmaceuticals
- Jesse's Journey
- Jiangsu Aosaikang Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Tainuo
- Johns Hopkins University
- Johnson & Johnson
- Johnson & Johnson Innovation
- Jolt Health
- Jubilant Radiopharma
- Jubilant Therapeutics
- Juniper Biologics
- Junshi Biosciences
- Juvena Therapeutics
- JW Pharmaceutical
- Kali Therapeutics
- Kalytera Therapeutics
- Kansas State University
- Karolinska Institute
- Kashiv BioSciences
- Kawasaki Medical School
- Keck School of Medicine of USC
- Kelyniam Global
- Kennedy Institute of Rheumatology
- KeyBioScience
- KeyCare
- KFx Medical
- Kinea Bio
- Kiniksa Pharmaceuticals
- KiOmed Pharma
- Kitov Pharma
- Kolon Life Science
- Komodo Health
- Kowa Pharmaceuticals America
- Kuhnil Pharmaceuticals
- KYE Pharmaceuticals
- Kyowa Hakko Kirin
- Kyverna Therapeutics
- Laboratories Acbel
- LABORATORIOS SAVAL
- Laurel Venture Capital
- Leadiant Biosciences
- Les Laboratoires Servier
- Level Brands
- Levolta Pharmaceuticals
- Lexicon Pharmaceuticals
- LG Chem
- Lima Corporate
- Link Health
- Lipocine
- Locana
- London School of Medicine and Dentistry
- Lonza
- Lucy Biotech
- Ludwig Institute for Cancer Research
- Lumicera Health Services
- Lupin
- Lynk Pharmaceuticals
- Maastricht University
- Mabwell Bioscience
- mAbXience
- MainPointe
- Marathon Pharmaceuticals
- Marina Biotech
- Maryland Stem Cell Research Fund
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Max-Planck
- Max Biopharma
- Maxx Medical
- Maxx Orthopedics
- Mayo Clinic
- MC10
- McMaster University
- MDA Venture Philanthropy
- Medac
- Medacta
- Medera
- Medexus Pharmaceuticals
- Mediar Therapeutics
- Medicardia Health
- Medidata Solutions
- MedImmune
- Medipost
- Medolife Rx
- MedShape
- Menarini
- Merck and Co
- Merck KGaA
- Mesoblast
- Mestag Therapeutics
- Metabolon
- Methuselah Foundation
- Metrion Biosciences
- MHC Medical Products
- Microdrop
- MiMedx
- Miravo Healthcare
- miRecule
- Mithra Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Moebius Medical
- Momenta Pharmaceuticals
- MoonLake Immunotherapeutics
- Morphic Therapeutic
- Morris Animal Foundation
- MoveUP
- mSKIL
- MS Pharma
- MTF Biologics
- Mundipharma
- Muscle Activation Technique
- Muscular Dystrophy Association
- Musculoskeletal Transplant Foundation
- Mylan Laboratories
- Mylan Pharmaceuticals
- Myonexus Therapeutics
- MYOS
- Myriad Genetics
- myTomorrows
- Nano-X Imaging
- NanoMosaic
- Nanotherapeutics
- National Human Genome Research Institute
- National Institute of Arthritis and Musculoskeletal Diseases
- National Institute on Aging
- National Institutes of Health
- National Psoriasis Foundation
- National Science Foundation
- Nationwide Children’s Hospital
- Navidea Biopharmaceuticals
- Navitas
- NeoDynamics
- Nestle
- Neuro42
- Neurocrine Biosciences
- Neuronoff
- NeuroVive Pharmaceutical
- NeuX Technologies
- NewBiologix
- Nippon Shinyaku
- Nipro Corporation
- Nordic Bioscience
- Nordic Pharma Group
- Northway Biotechpharma
- Northwell Health
- Northwestern University
- NovaQuest
- Novartis
- NT Pharma
- Nuevolution
- Nuritas
- Nuvo Research
- nView Medical
- Ohio State Innovation Foundation
- Ohio State University
- OliX Pharmaceuticals
- OmniaBio
- OncoArendi Therapeutics
- Oncodesign
- Onkos Surgical
- Ono Pharmaceutical
- Open University of Israel
- OPUM
- Orebro University
- Organon
- Organovo
- Orthocell
- Orthofix Medical
- OrthoGrid Systems
- Orthopaedic Foot & Ankle Center
- Ortho Regenerative Technologies
- OrthoSensor
- Ortoma
- Osteolabs
- Osteopore International
- Oxford Biomedica Solutions
- Paladin Labs
- Palisade Bio
- Paragon 28
- ParcelShield
- Parent Project Muscular Dystrophy
- Parvizi Surgical Innovation
- Patient-Centered Outcomes Research Institute
- Pennsylvania State University
- PeptiDream
- PetVivo
- Pfenex
- Pfizer
- PharmaLegacy Laboratories
- Pharmanovia
- Pharmapark
- Poietis
- Precision BioSciences
- Pregene Biopharma
- Premier Inc
- Prevail Therapeutics
- Prime Therapeutics
- PrinterPrezz
- Prometheus Laboratories
- Promimic
- Propella Therapeutics
- Provider Network of America
- PTC Therapeutics
- pt Health
- Purdue Pharma
- Purdue Research Foundation
- QED Therapeutics
- QuantHealth
- Queen Mary University of London
- Quest Diagnostics
- Radius Health
- Radius Pharmaceuticals
- Ramot at Tel Aviv University
- Rani Therapeutics
- Rebel Edibles
- Recombinetics
- Recursion
- Regen BioPharma
- Regeneron Pharmaceuticals
- Regeneus
- Regenstrief Institute
- Regenxbio
- Relation Therapeutics
- Remedium Bio
- Remission Medical
- Replicel Life Sciences
- Restoration Biologics
- RevBio
- ReveraGen BioPharma
- Revive Therapeutics
- Revolo Biotherapeutics
- Rheumatology Research Foundation
- Ribon Therapeutics
- Rigenerand
- Riptide Bioscience
- RMX Biopharma
- Roche
- Rocket Pharmaceuticals
- ROMEG Therapeutics
- RoosterBio
- Saint Louis University
- Samsung Bioepis
- Sanara MedTech
- Sandoz
- Sangamo Therapeutics
- Sanguine
- Sanofi
- Santhera Pharmaceuticals
- Saphetor
- Sarcomatrix Therapeutics
- Sarepta Therapeutics
- Satellos Bioscience
- Sayre Therapeutics
- Scipher Medicine
- Scribe Therapeutics
- Scripps Research Institute
- Scriptr Global
- Second Genome
- SecondWave Systems
- Selecta Biosciences
- Serenus.AI
- Shionogi
- Shriners Hospital for Children
- Si-Bone
- Simcere Pharmaceutical
- SimonMed Imaging
- Singapore Sengkang General Hospital
- SiSaf
- Sites Medical
- Skyhawk Therapeutics
- Sleip
- SmartCella
- Smith & Nephew
- Solarea Bio
- Solid Biosciences
- Solve GNE
- SomaLogic
- Somite Therapeutics
- Sorrento Therapeutics
- Southwest Research Institute
- Southwest Transplant Alliance
- Spero Therapeutics
- Spotlight Innovation
- SQI Diagnostics
- STADA Arzneimittel
- Standigm
- Stempeutics
- Strand Life Sciences
- StrideBio
- StrongPath
- Strykagen
- Stryker
- Summit Therapeutics
- Sun Pharmaceutical
- Sway Medical
- Swedish Bactiguard
- Swedish Orphan Biovitrum
- SynAct Pharma
- Synastra Biotechnology
- Synpromics
- Synthego
- Synthetic Biologics
- Syntr Health Technologies
- Tabuk Pharmaceutical
- Taiwan Liposome Company
- Takeda Pharmaceutical
- Technomark Life Sciences
- Teijin
- Teikoku Seiyaku
- Telomir Pharmaceuticals
- TeraRecon
- Teva Pharmaceutical Industries
- Teva Pharmaceuticals USA
- Tevard Biosciences
- Texas Christian University
- The Arthritis Society
- The Cyprus Institute of Neurology and Genetics
- Theradaptive
- Theramex
- Thermo Fisher Scientific
- THINK Surgical
- Thuasne and Townsend Design
- Tissue Dynamics
- TissueGene
- Tissue Genesis
- Tissue Regenix
- TiumBio
- TLC BioSciences
- Toshiba Medical Systems Corporation
- Total Joint Orthopedics
- Tow Foundation
- TR-Pharm
- TracPatch Health
- Transcenta
- Transdermal Delivery Solutions
- TRB Chemedica
- TrialSpark
- Tufts University
- Turner Imaging Systems
- UCB
- Ultragenyx Pharmaceuticals
- Unilife
- United Immunity
- United Orthopedic Group
- University City Science Center
- University Gottingen
- University of Basel
- University of Bern
- University of British Columbia
- University of California
- San Diego (UCSD) School of Medicine
- University of California Berkeley
- University of California Irvine
- University of California Los Angeles
- University of California San Francisco
- University of Florida
- University of Illinois
- University of Illinois Urbana-Champaign
- University of Iowa
- University of Kansas
- University of Lausanne
- University of Liverpool
- University of L’Aquila
- University of Maryland Baltimore
- University of Massachusetts Medical School
- University of Miami
- University of Michigan
- University of Minnesota
- University of Missouri
- University of Ottowa
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Sydney
- University of Texas Southwestern Medical Center
- University of Vermont
- University of Verona
- University of Virginia
- University of Washington
- University of Western Australia
- Urica Therapeutics
- US Army
- Vandria
- Variant Bio
- V ClinBio
- Verge Genomics
- Verily
- VeriSIM Life
- Verity Pharmaceuticals
- Vertex Pharmaceuticals
- VetStem
- VIB
- Victoria University
- Virginia Commonwealth University
- Virpax Pharmaceuticals
- Viscogliosi Brothers
- Vitalli Bio
- Vita Therapeutics
- Vizient
- Voronoi
- Voyager Therapeutics
- Wake Research Associates
- Walloon Region Investment Fund
- Weill Cornell Medical College
- WellDyne
- WestGene Biopharma
- William Harvey Research Instutute
- WishBone Medical
- WorldCare Clinical
- WuXi Biologics
- Xlife Sciences
- Yale University
- Yposkesi
- Zentiva
- Zimmer Biomet
- Zoetis
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
